Cansino Biologics Stock Earnings Per Share
CASBF Stock | USD 1.86 0.20 9.71% |
CanSino Biologics fundamentals help investors to digest information that contributes to CanSino Biologics' financial success or failures. It also enables traders to predict the movement of CanSino Pink Sheet. The fundamental analysis module provides a way to measure CanSino Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CanSino Biologics pink sheet.
CanSino |
CanSino Earnings Per Share Analysis
CanSino Biologics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current CanSino Biologics Earnings Per Share | 0.59 X |
Most of CanSino Biologics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CanSino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Competition |
According to the company disclosure, CanSino Biologics has an Earnings Per Share of 0.59 times. This is 92.95% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all United States stocks is 81.09% higher than that of the company.
CanSino Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CanSino Biologics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics of similar companies.CanSino Biologics is currently under evaluation in earnings per share category among related companies.
CanSino Fundamentals
Return On Equity | 0.0111 | |||
Return On Asset | -0.0207 | |||
Profit Margin | 0.06 % | |||
Operating Margin | (0.19) % | |||
Current Valuation | 3.58 B | |||
Shares Outstanding | 114.78 M | |||
Shares Owned By Insiders | 26.70 % | |||
Shares Owned By Institutions | 38.17 % | |||
Price To Earning | 19.25 X | |||
Price To Book | 2.30 X | |||
Price To Sales | 2.51 X | |||
Revenue | 4.3 B | |||
Gross Profit | 3 B | |||
EBITDA | 2.05 B | |||
Net Income | 1.91 B | |||
Cash And Equivalents | 7 B | |||
Cash Per Share | 28.36 X | |||
Total Debt | 40 M | |||
Debt To Equity | 0.26 % | |||
Current Ratio | 2.99 X | |||
Book Value Per Share | 29.22 X | |||
Cash Flow From Operations | 2.05 B | |||
Earnings Per Share | 0.59 X | |||
Number Of Employees | 1.95 K | |||
Beta | 0.61 | |||
Market Capitalization | 3.15 B | |||
Total Asset | 11.87 B | |||
Z Score | 46.8 | |||
Annual Yield | 0.01 % | |||
Net Asset | 11.87 B | |||
Last Dividend Paid | 0.8 |
About CanSino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CanSino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2191 people.
Pair Trading with CanSino Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CanSino Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CanSino Biologics will appreciate offsetting losses from the drop in the long position's value.Moving against CanSino Pink Sheet
0.77 | TEVA | Teva Pharmaceutical | PairCorr |
0.68 | MKKGY | Merck KGaA ADR | PairCorr |
0.67 | MKGAF | MERCK Kommanditgesells | PairCorr |
0.62 | WF | Woori Financial Group Financial Report 21st of May 2024 | PairCorr |
0.6 | KB | KB Financial Group Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to CanSino Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CanSino Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CanSino Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CanSino Biologics to buy it.
The correlation of CanSino Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CanSino Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CanSino Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CanSino Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CanSino Biologics Piotroski F Score and CanSino Biologics Altman Z Score analysis. Note that the CanSino Biologics information on this page should be used as a complementary analysis to other CanSino Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for CanSino Pink Sheet analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |